A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

2,831

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

February 29, 2008

Conditions
Meningococcal MeningitisMeningococcal Infections
Interventions
BIOLOGICAL

Meningococcal ACWY Polysaccharide Vaccine

One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.

BIOLOGICAL

MenACWY CRM (19 to 55 years)

One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.

BIOLOGICAL

Meningococcal ACWY Conjugate Vaccine

One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.

BIOLOGICAL

Novartis MenACWY Vaccine (56 to 65 Years)

One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.

Trial Locations (2)

C1406DGI

Buenos Aires, Argentina, Buenos Aires

Unknown

Cali, Colombia; Bogota, Colombia, Cali; Bogota

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY